The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally. This will enable the investigators to study this disease in depth. With a better understanding, the investigators can aim to develop early screening programs for at-risk patients, raising awareness among non-cardiologists. As amyloid-specific therapies have now become available in Thailand, the findings of this registry can be helpful for epidemiological studies in Thailand.
Study Type
OBSERVATIONAL
Enrollment
105
No intervention
Faculty of Medicine at Chulalongkorn University
Bangkok, Thailand
NOT_YET_RECRUITINGFaculty of Medicine Ramathibodi hospital, Mahidol University
Bangkok, Thailand
NOT_YET_RECRUITINGFaculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
Rate of death
Time frame: 3 years
Rate of heart failure hospitalization
Time frame: 3 years
Transthyretin (ATTR) amyloidosis medication
Rate of use and rate of adverse effect of Transthyretin (ATTR) amyloidosis medication
Time frame: 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Phramongkutklao Hospital
Bangkok, Thailand
NOT_YET_RECRUITINGFaculty of Medicine Chiang Mai University
Chiang Mai, Thailand
NOT_YET_RECRUITINGQueen Sirikit Heart Center of The Northeast
Khon Kaen, Thailand
NOT_YET_RECRUITINGFaculty of Medicine, Thammasat University
Pathum Thani, Thailand
NOT_YET_RECRUITINGPrince of Songkla University
Songkhla, Thailand
RECRUITING